← Back to Search

Behavioural Intervention

Mobile App for Arthritis (RAPID-PsA Trial)

N/A
Recruiting
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Using guselkumab, infliximab, golimumab, or ustekinumab
At least 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights

Summary

This trial aims to test a new version of a smartphone app for arthritis over 12 months. Researchers will compare how often people visit their healthcare providers before and after using the app. They will also compare

Who is the study for?
This trial is for adults over 18 with Psoriatic Arthritis (PsA), diagnosed by a specialist, who've had at least two appointments in the past year. Participants must speak English and own an Android or iPhone smartphone. They should be using specific arthritis medications like guselkumab or infliximab.
What is being tested?
The study tests if a new version of the Arthritis app can change how often patients need to visit doctors. It compares visit frequency before and after introducing the app, and against a control group not using the app, over 12 months.
What are the potential side effects?
Since this trial involves a mobile application rather than medication, traditional side effects are not expected. However, users may experience issues related to usability such as difficulty navigating the app or technical glitches.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am currently using guselkumab, infliximab, golimumab, or ustekinumab.
Select...
I am 18 years old or older.
Select...
I have been diagnosed with Psoriatic Arthritis by a specialist and have had at least two appointments in the last year.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Visit Frequency
Secondary study objectives
Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue short form
Patient Reported Outcomes Measurement Information System (PROMIS) Function short form
Patient Reported Outcomes Measurement Information System (PROMIS) Pain short form
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Mobile ApplicationExperimental Treatment1 Intervention
This arm of the study will contain half the study population after randomization. The participants in this arm will receive the EHR integrated app and follow a 12-month interrupted time series analysis (ITSA) design. n = 200
Group II: ControlsActive Control1 Intervention
This arm of the study will contain half the study population after randomization. The participants in this arm will be from the same rheumatologists as the experimental participants and will be used as concurrent controls by accessing their data on visits from the EHR during the same time period. n = 200

Find a Location

Who is running the clinical trial?

Brigham and Women's HospitalLead Sponsor
1,653 Previous Clinical Trials
11,490,635 Total Patients Enrolled
31 Trials studying Arthritis
590,583 Patients Enrolled for Arthritis
Janssen Scientific Affairs, LLCIndustry Sponsor
161 Previous Clinical Trials
579,541 Total Patients Enrolled
3 Trials studying Arthritis
1,729 Patients Enrolled for Arthritis
~257 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top